Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (14547)	12/7/2004 9:00:37 PM
From: Tomato	Read Replies (1) \| Respond to of 52153

Which is why I would dread to meet you all. I like my fantasy masks.) You ought to take a vacation trip to the left coast and the Rick Harmon Chapter of Biofreaks will convene in your honor at the local preferred watering hole. I'll have to remember to take my zocor, pepsid, and lisinopril before I go. ;-) Wayne

To: tom pope who wrote (14547)	12/7/2004 11:39:43 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Merck/Medco slammed me from Lipitor to Zocor When Merck and Medco were joined at the waist that wasn't hard to explain. The antitrust guys should have been all over that one at the outset. This recent Kaiser switch is more puzzling. It may be part of a bigger negotiation with Merck for multiple drugs, or alternatively they are looking forward and positioning themselves for 2006. But I can't really imagine that's the case. There seems to be no rhyme or reason for why some drugs are on formulary and others are not. I use Medco, and it seems totally random which statins they cover - it's certainly not done by price or by efficacy. (But one apparent legacy of their previous link with Merck is that they have a more generous coverage limit for Merck's Maxalt than for any of the others.) Peter